Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Long-term follow-up reveals sustained benefit of dual CD19/CD22 CAR T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

JPJuan‐juan PengNWNa WangJXJinghuan Xu

Discussion

Loading...

Member takes

Overview

Long-term follow-up shows improved survival and disease control in TP53-altered B-cell lymphoma, suggesting dual-target CAR T-cell therapy and transplantation is a promising approach.

Key Points

  • Overall survival improved significantly in patients receiving ASCT with CAR T-cell therapy, demonstrating a potential new standard for treatment.
  • 5-year overall survival was 70.2% with sequential ASCT-CAR T-cell therapy, contrasting with 40.0% for monotherapy, emphasizing the treatment's effectiveness.
  • Long-term follow-up of 122 patients assessed clinical outcomes and prognostic factors, guided by multivariate analysis for robust results.
  • These findings underscore the need for precision immunotherapy strategies as dual-target therapy shows promise in high-risk B-cell non-Hodgkin lymphoma.

Cite This Study

Peng et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df33https://doi.org/10.1182/blood-2025-3712
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Impact of TP53 mutations on survival outcomes in the CAR-T era of large B-cell lymphoma2025 · 1 citations
  2. 2Impact of TP53 mutation on CD19-chimeric antigen receptor T-cell therapy in large B-cell lymphoma2025
  3. 3Long-term follow-up results of nonremission relapsed/refractory DLBCL with CAR T-cell cocktail therapy alone or in combination with ASCT2025
  4. 4Sequential CD19/CD22 CAR-T cell therapy following ASCT shows improved efficacy versus CAR-T alone in relapsed/refractory large B-cell lymphoma2025
  5. 5Safety and efficacy of CD19/CD22/CD20 multi-targeted CAR-T therapy in patients with refractory/relapsed B-cell non-Hodgkin lymphoma2025 · 1 citations